Anifrolumab, an Anti-Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus

Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study

(2016) Munther Khamashta et al.   ANNALS OF THE RHEUMATIC DISEASES

A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-α) in patients with systemic lupus erythematosus (ROSE)

(2015) Kenneth C Kalunian et al.   ANNALS OF THE RHEUMATIC DISEASES

Targeting Interferons in Systemic Lupus Erythematosus: Current and Future Prospects

(2015) Alexis Mathian et al.   DRUGS

Molecular basis for antagonistic activity of anifrolumab, an anti-interferon–α receptor 1 antibody

(2015) Li Peng et al.   mAbs

Targeting of type I interferon in systemic autoimmune diseases

(2015) Mary K. Crow et al.   Translational Research

A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study

(2014) R A Furie et al.   ANNALS OF THE RHEUMATIC DISEASES

Advances in understanding the role of type I interferons in systemic lupus erythematosus

(2014) Mary K. Crow   CURRENT OPINION IN RHEUMATOLOGY

Type I Interferon in the Pathogenesis of Lupus

(2014) M. K. Crow   JOURNAL OF IMMUNOLOGY

Dose-escalation of human anti-interferon-α receptor monoclonal antibody MEDI-546 in subjects with systemic sclerosis: a phase 1, multicenter, open label study

(2014) Avram Goldberg et al.   ARTHRITIS RESEARCH & THERAPY

Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study

(2013) Daniel J Wallace et al.   ANNALS OF THE RHEUMATIC DISEASES

Pharmacogenomics and Translational Simulations to Bridge Indications for an Anti-Interferon-α Receptor Antibody

(2013) B Wang et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Type I interferon blockade in systemic lupus erythematosus: where do we stand?

(2013) B. R. Lauwerys et al.   RHEUMATOLOGY

Overall and Cause-Specific Mortality in Patients With Systemic Lupus Erythematosus: A Meta-Analysis of Observational Studies

(2013) Marko Yurkovich et al.   ARTHRITIS CARE & RESEARCH

The economic burden of systemic lupus erythematosus

(2012) Pantelis Panopalis et al.   BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY

Emerging therapies for systemic lupus erythematosus — Focus on targeting interferon-alpha

(2012) Eben I. Lichtman et al.   CLINICAL IMMUNOLOGY

Glucocorticoid use and abuse in SLE

(2012) G. Ruiz-Irastorza et al.   RHEUMATOLOGY

Use of type I interferon-inducible mRNAs as pharmacodynamic markers and potential diagnostic markers in trials with sifalimumab, an anti-IFNα antibody, in systemic lupus erythematosus

(2012) Yihong Yao et al.   ARTHRITIS RESEARCH & THERAPY

Development of the CLASI as a Tool to Measure Disease Severity and Responsiveness to Therapy in Cutaneous Lupus Erythematosus

(2011) Rachel Klein et al.   ARCHIVES OF DERMATOLOGY

The type I interferon system in the development of lupus

(2011) Lars Rönnblom et al.   SEMINARS IN IMMUNOLOGY

Numerical scoring for the BILAG-2004 index

(2010) Chee-Seng Yee et al.   RHEUMATOLOGY

Building a Measure of Fatigue: The Functional Assessment of Chronic Illness Therapy Fatigue Scale

(2010) Eleanor Smith et al.   PM&R

Novel evidence-based systemic lupus erythematosus responder index

(2009) Richard A. Furie et al.   ARTHRITIS AND RHEUMATISM

Lupus: improving long-term prognosis

(2008) A Doria et al.   LUPUS